The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Jul 18, 2026
Snapshot (as of Jul 18, 2026): Novartis AG (NVS) pays a $4.58 annual dividend ($1.15 quarterly), yielding 2.96% at $153.76/share. Next ex-dividend date 2026-03-11. 6 consecutive years of dividend growth. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 2.96%
Annual Dividend: $4.58 per share
Payout Ratio: 61.0%
Ex-Dividend Date: 2026-03-11
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 26
Novartis AG dividend income comes from one of the world's largest pharmaceutical companies, focused on prescription medicines across oncology, immunology, neuroscience, and cardiovascular diseases. NVS currently yields 2.98%, with a trailing annual dividend rate of $4.5721 per share paid quarterly. The next ex-dividend date is March 11, 2026. With a beta of 0.495, NVS stock moves at roughly half the volatility of the broader market, which suits income investors who prioritize steadiness over price swings.
Novartis AG pays out 61.0% of earnings as dividends, a payout ratio classified as elevated (60–75%). That level is supported by a product portfolio anchored in prescription medicines with recurring demand across oncology, cardiovascular, and neuroscience therapies. Novartis AG dividend safety is further grounded in six consecutive years of increases, though a payout ratio at the upper end of this range leaves limited room to absorb an earnings decline without pressure on the dividend.
Novartis AG dividend history shows a CAGR of 4.7% per year from 2011 to 2025. Per-share payments grew from $2.1084 to $3.9940 over that window (2026 data is partial and excluded from this calculation). The largest annual increase in the window was 18.5% in 2020, while growth in other years was considerably more modest, reflecting the uneven pace that income investors should expect from NVS.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +6.0% | $3.36 (2022) | $3.99 (2025) |
| 5-Year | +5.6% | $3.04 (2020) | $3.99 (2025) |
| 10-Year | +4.7% | $2.52 (2015) | $3.99 (2025) |
NVS fits dividend investors who want pharmaceutical sector exposure with a moderate yield and low price volatility. The current yield of 2.98% sits above its 5-year average of 2.24%, meaning today's entry point delivers more income than the historical norm. Growth has averaged 4.7% annually, which keeps pace with inflation but is not fast enough to dramatically compound income over time. The trade-off is a payout ratio of 61.0%, classified as moderate (2–4%) yield territory with an elevated payout, leaving less cushion than lower-ratio peers. What investors get is a pharmaceutical business with recurring prescription demand and six straight years of dividend increases.
| Payment Date | Amount per Share |
|---|---|
| 2026-03-11 | $4.7730 |
| 2025-03-12 | $3.9940 |
| 2024-03-07 | $3.7400 |
| 2023-03-09 | $3.4690 |
| 2022-03-08 | $3.3570 |
| 2021-03-04 | $3.3780 |
| 2020-03-03 | $3.0420 |
| 2019-03-04 | $2.5672 |
| 2018-03-06 | $2.6676 |
| 2017-03-01 | $2.4606 |
| Year | Total Dividends |
|---|---|
| 2026 | $4.7730 |
| 2025 | $3.9940 |
| 2024 | $3.7400 |
| 2023 | $3.4690 |
| 2022 | $3.3570 |
Project income from NVS with the NVS dividend calculator or track your full portfolio with the dividend tracker.